Bcl-xL inhibitors (A-1155463 and A-1331852, for example) have emerged as a very interesting option, since they appear to have the potential to enhance the efficacy of docetaxel in solid tumors and avoid the exacerbation of neutropenia observed with navitoclax (because inhibits both Bcl-xL and Bcl-2) [35]. This evidence concerns the gene BCL2 and neutropenia.